Thomas Colarusso

Join Novogene at The Festival of Genomics & Biodata in Boston, MA! Connect with our experts at booth #58 for insights into genomics and your sequencing needs!

13

Criterium’s Oncology Consortia members make waves at American Society of Clinical Oncology (ASCO) 2024 annual conference, sharing valuable insights and progress from their innovative research models and clinical trials. https://lnkd.in/e3hnqdze #clinicaltrials #oncology #ASCO24

3

1 Comment

Criterium’s Oncology Consortia members make waves at American Society of Clinical Oncology (ASCO) 2024 annual conference, sharing valuable insights and progress from their innovative research models and clinical trials. https://lnkd.in/e3hnqdze #clinicaltrials #oncology #ASCO24

1

[CASE STUDY] Learn how a global biopharma company centralized data, streamlined workflows, and enhanced collaboration for its GLP and non-regulated toxicologic pathology studies with Concentriq for Research. https://bit.ly/3OaXmGA #digitalpathology

21

🎤 Don't miss your chance to be part of the dynamic roundtable discussion on "Use of AI to Reduce Timeline of Lead Generation to Optimization" at the AI in Drug Discovery Xchange, Maryland 2024. 🏆 COMPLIMENTARY REGISTRATION: https://lnkd.in/e5HJgziP 🏆 This session, led by Industry Expert Indranath Ghosh, Director of Medicinal Chemistry at Congruence Therapeutics promises to deliver invaluable insights into the latest AI-driven strategies that are revolutionizing drug discovery. 🕵Key Discussion Points: 1️⃣ Which AI-driven approaches have shown the most success in reducing the timeline from lead generation to optimization? 2️⃣ How can machine learning models be integrated into the lead optimization process to enhance prediction accuracy and reduce experimental iterations? 3️⃣ What are the necessary criteria for model validation in this context? 4️⃣ How can organizations ensure robust data acquisition and pre-processing for model training? 🗣️ Dr. Ghosh is a seasoned medicinal chemist with over 15 years of experience in drug discovery, specializing in CNS, inflammation, and oncology therapies. Currently serving as Director of Medicinal Chemistry at Congruence Therapeutics, he leads the GBA1 Allosteric Modulator Program. Previously, Dr. Ghosh held senior roles at GlycoMimetics, Inc., and co-led the 5HT2C-5HT6 Dual Ligand Program at Galenea Corporation to discover an atypical antipsychotic with pro-cognitive efficacy. He holds a Ph.D. from Dartmouth College and conducted post-doctoral research at Harvard University, with numerous patents and publications. 📚 Lead Generation & Optimization Track 📅 Thursday, 31 October, 2024 🕒 09:05 - 10:05 📍 Marriott Hotel, Maryland 💊Only available for Senior Scientists and above, from Bio and Pharma companies, with a drug pipeline. #AIinPharma #DrugDevelopment #HealthTech #AIResearch #ClinicalTrials #Biopharma #Chemoinformatics #AIModels #InnovationInMedicine #BiotechInnovation #PharmaceuticalScience #MachineLearningInMedicine #AIandML #DataScience #AIRoundtable #MedChem #DrugDesign #PharmaInnovation #TechInHealth #FutureOfMedicine #BiomedicalResearch #LeadOptimization #MedTech #AICommunity #ScientificRoundtable #hubXchange #Xchanges #Roundtable #FreePass #RegisterNow #ComplimentaryPass

37

1 Comment

Our Q2 2024 MARA Dev update delves into how we're integrating tools, knowledge, and workflows to transform scientific inquiry. Learn more in our blog. #LLM #DrugDiscovery https://bit.ly/44V9Nh5

3

We are transforming the future of biopharma. Discover the Power of SDC - https://lnkd.in/ghruHFDE. Synkrino Development Company partners with biotech to finance and develop innovative high impact therapeutics programs. We serve the entire pharma ecosystem of patients, prescribers, payers, biotechs, and pharma companies by financing, accelerating, and pushing forward drug candidates with the potential to significantly improve the standard of care – offering a new range of therapeutic options that balance price and treatment outcome. Our process creates portfolios of orthogonal assets (biological target, disease indication, modality) with the aim of de-risking biotech investments for institutional investors. We partner with biotech on an asset basis – not a company basis – creating a stream of uncorrelated cash flows with a superior return-on-investment profile. https://synkrino.dev

15

#Webinar #DDI #CellBasedAssays 🔍INDIGO's webinar page is full of helpful resources pertaining to receptors, cell-based assays, and their use in drug discovery or environmental testing! 💡 🧫Environmental Monitoring: Evaluating Cellular Response Pathways in Complex Mixtures In this webinar, Dr. Jack Vanden Heuvel will review recent environmental toxicology research that employs an alternative workflow for evaluating water samples. This method allows researchers to maximize the number of receptors and pathways evaluated while providing better throughput and toxicologic information. 📚How to Better Predict Potential Drug Interactions Early in the Discovery Process Drug-drug interactions (DDI) are a cause of many adverse outcomes clinically, costing the health care system over a billion dollars. Thus, there is increasing interest in understanding the risk posed by certain drug candidates early in the discovery process. Fortunately, many aspects of DDI are predictable based on our increasing understanding of the mechanisms of altered absorption, distribution, metabolism, and excretion (ADME) and improved tools for screening for potential liabilities early in the drug-discovery process. These tools include in vitro assays that look at pharmacokinetic interactions through changing the activity of enzymes involved in the clearance of drugs, such as cytochromes P450 (CYPs). 🌿Save Time and Money When Prioritizing Drug Candidates: Using Cell-Based Reporter Assays for Nuclear Receptor Profiling In preclinical drug discovery, the identification of potential drug candidates requires a thorough evaluation of their pharmacological effects, as well as any potential off-target liabilities. Nuclear receptors play a crucial role in many physiological processes and have emerged as important targets for drug discovery. However, potential drugs often have multiple effects, often within a gene family, leading to potential polypharmacology, where new beneficial effects, as well as off-target liabilities, can be discovered. To triage or prioritize data, dose-response experiments with nuclear receptor assays can be used. In this presentation, we discuss the use of cell-based reporter assays for nuclear receptor profiling and how this strategy can help identify potential drug candidates with desirable pharmacological properties and reduced off-target effects. Check out these webinars and more on our website! https://hubs.la/Q02GKmlS0

1

#Webinar #DDI #CellBasedAssays 🔍INDIGO's webinar page is full of helpful resources pertaining to receptors, cell-based assays, and their use in drug discovery or environmental testing! 💡 🧫Environmental Monitoring: Evaluating Cellular Response Pathways in Complex Mixtures In this webinar, Dr. Jack Vanden Heuvel will review recent environmental toxicology research that employs an alternative workflow for evaluating water samples. This method allows researchers to maximize the number of receptors and pathways evaluated while providing better throughput and toxicologic information. 📚How to Better Predict Potential Drug Interactions Early in the Discovery Process Drug-drug interactions (DDI) are a cause of many adverse outcomes clinically, costing the health care system over a billion dollars. Thus, there is increasing interest in understanding the risk posed by certain drug candidates early in the discovery process. Fortunately, many aspects of DDI are predictable based on our increasing understanding of the mechanisms of altered absorption, distribution, metabolism, and excretion (ADME) and improved tools for screening for potential liabilities early in the drug-discovery process. These tools include in vitro assays that look at pharmacokinetic interactions through changing the activity of enzymes involved in the clearance of drugs, such as cytochromes P450 (CYPs). 🌿Save Time and Money When Prioritizing Drug Candidates: Using Cell-Based Reporter Assays for Nuclear Receptor Profiling In preclinical drug discovery, the identification of potential drug candidates requires a thorough evaluation of their pharmacological effects, as well as any potential off-target liabilities. Nuclear receptors play a crucial role in many physiological processes and have emerged as important targets for drug discovery. However, potential drugs often have multiple effects, often within a gene family, leading to potential polypharmacology, where new beneficial effects, as well as off-target liabilities, can be discovered. To triage or prioritize data, dose-response experiments with nuclear receptor assays can be used. In this presentation, we discuss the use of cell-based reporter assays for nuclear receptor profiling and how this strategy can help identify potential drug candidates with desirable pharmacological properties and reduced off-target effects. Check out these webinars and more on our website! https://hubs.ly/Q02V5pCf0

5

Improving The Clinical Trial Ecosystem: A Call To Stakeholder Alignment https://lnkd.in/edrwxW_U - By Rob Freishtat, MD, MPH In theory, all of the stakeholders in drug development — investors, scientists, regulators, and patients — share the common goal of creating safe and effective drugs.

2

If you’re still using traditional methods for identifying drug diversion, your workflow is likely drowning in data from various sources, resulting in disorganized reports. At Protenus, we do things differently to address drug diversion. 💡 Our case-based approach with AI prioritizes high-risk incidents, streamlining your workflow without the need for manual audits. Watch this quick video to learn how to ditch time-consuming investigations and embrace improved efficiency. 👇 #Healthcare #DrugDiversion #HealthcareCompliance #hospitals

2

GenomeWeb reports on Nucleai striking a deal to integrate its predictive biomarker technologies into Proscia cloud-based Concentriq digital pathology platform. This partnership will enable more pathologists and clinicians to convert the complex data from patient biopsies into precise, actionable insights that can drive better clinical trial and diagnostic decisions. #AI #spatialbiology #precisionmedicine #biomarker #diagnostics https://lnkd.in/e94gQQPe

8

The FDA is exploring the transformative potential of synthetic data in advancing in-silico clinical trials and regulatory evaluations. They’ve recently published a review article, "Synthetic Data in Radiological Imaging: Current State and Future Outlook". Link: https://lnkd.in/gXct95HT But why is synthetic data so pivotal for medical AI, particularly in radiology? Synthetic data replicates the statistical properties of real patient data but is created using computational techniques. It bypasses the challenges of acquiring sensitive, annotated datasets while maintaining privacy and compliance. 𝐁𝐞𝐧𝐞𝐟𝐢𝐭𝐬 𝐟𝐨𝐫 𝐀𝐈 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 → Synthetic data enriches underrepresented classes, improving training for AI models. → It generates rare cases that are otherwise difficult to source, enhancing AI robustness. → Removes risks associated with patient harm or data exposure, adhering to stringent privacy laws. → Scalable synthetic datasets reduce dependency on costly clinical data collection. → Enables virtual testing of devices and treatments, shortening innovation cycles while maintaining regulatory compliance.

4

How do we use Groovy when writing #Nextflow #Bioinformatics pipelines? Senior #Bioinformatics Engineer Jason Fan recently gave an insightful talk at the Boston 2024 #Nexflow Summit. Titled: "Get into the Groovy: using Groovy to model sample sheets, input and metadata, and more", this talk is a must-see for anyone interested in #Genomics and #Bioinformatics. Check out the video here: https://lnkd.in/gxNcFcHr

16

📢 News: Sonrai Accelerates Cancer Therapeutics Research with Advanced Analytics 📰 Read now: https://lnkd.in/dPMqy8D2 Sonrai’s AI data management and analysis technology will enable the Henri & Belinda Termeer Center for Targeted Therapies at Massachusetts General Hospital to manage vast multi-omic and multi-modal data to accelerate oncological research into personalized therapies using advanced analytics. 👋 To discuss how we can help advance your therapeutics development, book a chat with us: https://lnkd.in/dEnkdQdV #precisionmedicine #oncology #AI #dataanalytics #Sonrai #SonraiDiscovery #drugdevelopment #immunooncology #biomarkerdiscovery

33

📣There's still time to register! Join FDA and Clinical Trials Transformation Initiative (CTTI) August 6, 2024 (10:00 AM- 5:30 PM EDT) for a free hybrid public workshop on artificial intelligence (AI) in drug and biological product development. AI holds great potential to transform how drugs are developed, manufactured, and utilized. As with any innovation, AI use in drug development creates new and unique challenges that require both careful management and a risk-based regulatory framework that is built on sound regulatory science approaches. This public workshop will explore guiding principles that are being applied by innovators and regulators to promote the responsible use of AI in the development of safe and effective drugs. Register today ➡️ https://lnkd.in/eP99VH_2

232

8 Comments

Life Sciences DNA podcast, episode 11. Dimitrios Skaltsas CEO and co-founder of Intelligencia AI, sits down with Amar Drawid, Ph.D. to discuss how AI can support data-driven decision-making in drug development, improve the probability for success in clinical trials, and de-risk clinical development. Watch now - https://lnkd.in/g5t-PFW8 #AI #drugdevelopment #decisionmaking

10

1 Comment

Paradigm4 is thrilled to support Dr. Isaac Neuhaus, Executive Director of Computational Genomics at Bristol Myers Squibb, as he presents "Chatting with Bioinformatics Data" at BioTechX USA today! Join us at 11:45 AM for an insightful dive into how conversational AI is transforming the way we interact with bioinformatics data. Learn how this cutting-edge approach enables more intuitive and efficient data discovery, driving faster breakthroughs in genomics and precision medicine. We’re excited to see the future of data science in biotech unfold! Don’t miss this talk—it’s sure to inspire! 🌟 #BioTechXUSA #Bioinformatics #AIinHealthcare #PrecisionMedicine #BristolMyersSquibb #Paradigm4 #Genomics

12

1 Comment